APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?

Tatsuo Kanda; George K.K. Lau; Lai Wei; Mitsuhiko Moriyama; Ming Lung Yu; Wang Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S. Hamid; A. Kadir Dokmeci; Mamun-Al-Mahtab; Geofferey W. McCaughan; Jafri Wasim; Darrell H.G. Crawford; Jia Horng Kao; Osamu Yokosuka; Shiv Kumar Sarin; Masao Omata

doi:10.1007/s12072-018-9915-5

APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?

Tatsuo Kanda, George K.K. Lau, Lai Wei, Mitsuhiko Moriyama, Ming Lung Yu, Wang Long Chuang, Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Jose Sollano, Manoj Kumar, Ankur Jindal, Barjesh Chander Sharma, Saeed S. Hamid, A. Kadir Dokmeci, Mamun-Al-Mahtab, Geofferey W. McCaughan, Jafri Wasim, Darrell H.G. Crawford, Jia Horng Kao, Osamu YokosukaShiv Kumar Sarin, Masao Omata

Department of Medicine, Medical College, Pakistan

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

Chronic hepatitis C virus (HCV) infection is common among patients with chronic kidney disease (CKD) and those on hemodialysis due to nosocomial infections and past blood transfusions. While a majority of HCV-infected patients with end-stage renal disease are asymptomatic, some may ultimately experience decompensated liver diseases and hepatocellular carcinoma. Administration of a combination of elbasvir/grazoprevir for 12 weeks leads to high sustained virologic response (SVR) rates in patients with HCV genotypes (GTs) 1a, 1b or 4 and stage 4 or 5 CKD. Furthermore, a combination of glecaprevir/pibrentasvir for 8–16 weeks also results in high SVR rates in patients with all HCV GTs and stage 4 or 5 CKD. However, these regimens are contraindicated in the presence of advanced decompensated cirrhosis. Although sofosbuvir and/or ribavirin are not generally recommended for HCV-infected patients with severe renal impairment, sofosbuvir-based regimens may be appropriate for those with mild renal impairment. To eliminate HCV worldwide, HCV-infected patients with renal impairment should be treated with interferon-free therapies.

Original language	English
Pages (from-to)	103-109
Number of pages	7
Journal	Hepatology International
Volume	13
Issue number	2
DOIs	https://doi.org/10.1007/s12072-018-9915-5
Publication status	Published - 12 Mar 2019

Keywords

DAA
Guideline
HCV
Hemodialysis
Renal impairment
SVR

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12072-018-9915-5

Cite this

Kanda, T., Lau, G. K. K., Wei, L., Moriyama, M., Yu, M. L., Chuang, W. L., Ibrahim, A., Lesmana, C. R. A., Sollano, J., Kumar, M., Jindal, A., Sharma, B. C., Hamid, S. S., Dokmeci, A. K., Mamun-Al-Mahtab, McCaughan, G. W., Wasim, J., Crawford, D. H. G., Kao, J. H., ... Omata, M. (2019). APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatology International, 13(2), 103-109. https://doi.org/10.1007/s12072-018-9915-5

@article{77cd099a308c4a108987f3856dfe3510,

title = "APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?",

abstract = "Chronic hepatitis C virus (HCV) infection is common among patients with chronic kidney disease (CKD) and those on hemodialysis due to nosocomial infections and past blood transfusions. While a majority of HCV-infected patients with end-stage renal disease are asymptomatic, some may ultimately experience decompensated liver diseases and hepatocellular carcinoma. Administration of a combination of elbasvir/grazoprevir for 12 weeks leads to high sustained virologic response (SVR) rates in patients with HCV genotypes (GTs) 1a, 1b or 4 and stage 4 or 5 CKD. Furthermore, a combination of glecaprevir/pibrentasvir for 8–16 weeks also results in high SVR rates in patients with all HCV GTs and stage 4 or 5 CKD. However, these regimens are contraindicated in the presence of advanced decompensated cirrhosis. Although sofosbuvir and/or ribavirin are not generally recommended for HCV-infected patients with severe renal impairment, sofosbuvir-based regimens may be appropriate for those with mild renal impairment. To eliminate HCV worldwide, HCV-infected patients with renal impairment should be treated with interferon-free therapies.",

keywords = "DAA, Guideline, HCV, Hemodialysis, Renal impairment, SVR",

author = "Tatsuo Kanda and Lau, {George K.K.} and Lai Wei and Mitsuhiko Moriyama and Yu, {Ming Lung} and Chuang, {Wang Long} and Alaaeldin Ibrahim and Lesmana, {Cosmas Rinaldi Adithya} and Jose Sollano and Manoj Kumar and Ankur Jindal and Sharma, {Barjesh Chander} and Hamid, {Saeed S.} and Dokmeci, {A. Kadir} and Mamun-Al-Mahtab and McCaughan, {Geofferey W.} and Jafri Wasim and Crawford, {Darrell H.G.} and Kao, {Jia Horng} and Osamu Yokosuka and Sarin, {Shiv Kumar} and Masao Omata",

note = "Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2019",

month = mar,

day = "12",

doi = "10.1007/s12072-018-9915-5",

language = "English",

volume = "13",

pages = "103--109",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer New York",

number = "2",

}

Kanda, T, Lau, GKK, Wei, L, Moriyama, M, Yu, ML, Chuang, WL, Ibrahim, A, Lesmana, CRA, Sollano, J, Kumar, M, Jindal, A, Sharma, BC, Hamid, SS, Dokmeci, AK, Mamun-Al-Mahtab, McCaughan, GW, Wasim, J, Crawford, DHG, Kao, JH, Yokosuka, O, Sarin, SK & Omata, M 2019, 'APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?', Hepatology International, vol. 13, no. 2, pp. 103-109. https://doi.org/10.1007/s12072-018-9915-5

TY - JOUR

T1 - APASL clinical practice recommendation

T2 - how to treat HCV-infected patients with renal impairment?

AU - Kanda, Tatsuo

AU - Lau, George K.K.

AU - Wei, Lai

AU - Moriyama, Mitsuhiko

AU - Yu, Ming Lung

AU - Chuang, Wang Long

AU - Ibrahim, Alaaeldin

AU - Lesmana, Cosmas Rinaldi Adithya

AU - Sollano, Jose

AU - Kumar, Manoj

AU - Jindal, Ankur

AU - Sharma, Barjesh Chander

AU - Hamid, Saeed S.

AU - Dokmeci, A. Kadir

AU - Mamun-Al-Mahtab,

AU - McCaughan, Geofferey W.

AU - Wasim, Jafri

AU - Crawford, Darrell H.G.

AU - Kao, Jia Horng

AU - Yokosuka, Osamu

AU - Sarin, Shiv Kumar

AU - Omata, Masao

PY - 2019/3/12

Y1 - 2019/3/12

N2 - Chronic hepatitis C virus (HCV) infection is common among patients with chronic kidney disease (CKD) and those on hemodialysis due to nosocomial infections and past blood transfusions. While a majority of HCV-infected patients with end-stage renal disease are asymptomatic, some may ultimately experience decompensated liver diseases and hepatocellular carcinoma. Administration of a combination of elbasvir/grazoprevir for 12 weeks leads to high sustained virologic response (SVR) rates in patients with HCV genotypes (GTs) 1a, 1b or 4 and stage 4 or 5 CKD. Furthermore, a combination of glecaprevir/pibrentasvir for 8–16 weeks also results in high SVR rates in patients with all HCV GTs and stage 4 or 5 CKD. However, these regimens are contraindicated in the presence of advanced decompensated cirrhosis. Although sofosbuvir and/or ribavirin are not generally recommended for HCV-infected patients with severe renal impairment, sofosbuvir-based regimens may be appropriate for those with mild renal impairment. To eliminate HCV worldwide, HCV-infected patients with renal impairment should be treated with interferon-free therapies.

AB - Chronic hepatitis C virus (HCV) infection is common among patients with chronic kidney disease (CKD) and those on hemodialysis due to nosocomial infections and past blood transfusions. While a majority of HCV-infected patients with end-stage renal disease are asymptomatic, some may ultimately experience decompensated liver diseases and hepatocellular carcinoma. Administration of a combination of elbasvir/grazoprevir for 12 weeks leads to high sustained virologic response (SVR) rates in patients with HCV genotypes (GTs) 1a, 1b or 4 and stage 4 or 5 CKD. Furthermore, a combination of glecaprevir/pibrentasvir for 8–16 weeks also results in high SVR rates in patients with all HCV GTs and stage 4 or 5 CKD. However, these regimens are contraindicated in the presence of advanced decompensated cirrhosis. Although sofosbuvir and/or ribavirin are not generally recommended for HCV-infected patients with severe renal impairment, sofosbuvir-based regimens may be appropriate for those with mild renal impairment. To eliminate HCV worldwide, HCV-infected patients with renal impairment should be treated with interferon-free therapies.

KW - DAA

KW - Guideline

KW - HCV

KW - Hemodialysis

KW - Renal impairment

KW - SVR

UR - http://www.scopus.com/inward/record.url?scp=85058543693&partnerID=8YFLogxK

U2 - 10.1007/s12072-018-9915-5

DO - 10.1007/s12072-018-9915-5

M3 - Article

C2 - 30539517

AN - SCOPUS:85058543693

SN - 1936-0533

VL - 13

SP - 103

EP - 109

JO - Hepatology International

JF - Hepatology International

IS - 2

ER -

APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this